Alkermes plc. income statement
In fiscal 2025, Alkermes plc. reported revenue of $1.48bn, down 5.2% on the year before, operating income of $254m (a 17.2% margin) and net income of $242m, or $1.43 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Mar 2010 | 2011Mar 2011 | 2012Mar 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 178 | 187 | 390 | 596 | 619 | 628 | 746 | 903 | 1,094 | 1,171 | 1,039 | 1,174 | 1,112 | 1,663 | 1,558 | 1,476 | 1,754 |
| Cost of revenue | — | — | — | — | — | — | 132 | 155 | 176 | 180 | 178 | 197 | 218 | 253 | 245 | 196 | 300 |
| Gross profit | — | — | — | — | — | — | 614 | 749 | 918 | 991 | 860 | 976 | 894 | 1,410 | 1,312 | 1,279 | 1,453 |
| Research and development | 95 | 97 | 142 | — | 272 | 344 | 387 | 413 | 425 | 513 | 395 | 291 | 273 | 271 | 245 | 324 | 430 |
| Selling, general and administrative | 77 | 83 | 138 | — | 200 | 312 | 374 | 422 | 526 | 599 | 539 | 550 | 591 | 690 | 645 | 702 | 878 |
| Operating income | −43 | −46 | −88 | 34 | −87 | −224 | −209 | −148 | −99 | −175 | −112 | 98 | −6 | 414 | 421 | 254 | 64 |
| Interest expense | 6 | 3 | 28 | — | 13 | 13 | 15 | 12 | 15 | 14 | 9 | 11 | 13 | 23 | 23 | 12 | 87 |
| Income before tax | −45 | −46 | −114 | 13 | −14 | −224 | −214 | −143 | −127 | −197 | −97 | 88 | −31 | 422 | 444 | 291 | 11 |
| Income tax | −5 | −1 | −1 | −7 | 16 | 3 | −6 | 15 | 12 | −0 | 14 | 11 | 2 | −98 | 72 | 50 | 12 |
| Net income | −40 | −46 | −114 | 21 | −30 | −227 | −208 | −158 | −139 | −197 | −111 | −48 | −158 | 356 | 367 | 242 | −0 |
| Diluted EPS | −$0.42 | −$0.48 | −$0.99 | $0.14 | −$0.21 | −$1.52 | −$1.38 | −$1.03 | −$0.90 | −$1.25 | −$0.70 | −$0.29 | −$0.97 | $2.10 | $2.17 | $1.43 | −$0.00 |
| Diluted shares (average) | 95m | 96m | 115m | 144m | 145m | 149m | 151m | 153m | 155m | 157m | 159m | 165m | 164m | 170m | 169m | 169m | 171m |
| EBITDA | −18 | −37 | −40 | — | 11 | −139 | −114 | −49 | 5 | −95 | −31 | 176 | 72 | 489 | 449 | 281 | 145 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 430 | 307 | 391 | 394 | 385 | 393 | 496 | 480 |
| Cost of revenue | 62 | 49 | 49 | 52 | 46 | 62 | 98 | 94 |
| Gross profit | 368 | 257 | 341 | 343 | 338 | 331 | 398 | 386 |
| Research and development | 58 | 72 | 77 | 82 | 93 | 103 | 113 | 121 |
| Selling, general and administrative | 147 | 172 | 171 | 172 | 187 | 265 | 218 | 209 |
| Operating income | 163 | 14 | 93 | 89 | 58 | −48 | 18 | 36 |
| Interest expense | 5 | 0 | 0 | 0 | 12 | 21 | 26 | 28 |
| Income before tax | 170 | 25 | 105 | 101 | 60 | −62 | −2 | 15 |
| Income tax | 24 | 3 | 18 | 18 | 11 | 5 | −2 | −2 |
| Net income | 147 | 22 | 87 | 83 | 49 | −66 | 1 | 16 |
| Diluted EPS | $0.87 | $0.13 | $0.52 | $0.49 | $0.29 | −$0.40 | $0.00 | $0.09 |
| EBITDA | 170 | 21 | 101 | 97 | 62 | −29 | 49 | 63 |
Compare with peers
- Halozyme Therapeutics, Inc. income statement
- Insmed Inc income statement
- Madrigal Pharmaceuticals, Inc. income statement
- Moderna income statement
- Lakefront Biotherapeutics NV income statement
Head to head: ALKS vs HALOALKS vs INSMALKS vs MDGLALKS vs MRNA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies